West Central Gastroenterology — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$3,500	1
2024	Research	$17,719	11
2023	Research	$26,374	3
2022	Research	$29,566	6
2021	Research	$22,471	7
2020	Research	$30,407	3
2019	Research	$49,194	8

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $60,971 5 payments
Takeda Pharmaceuticals U.S.A., Inc. $56,839 21 payments
Ironwood Pharmaceuticals, Inc $21,624 2 payments
Shire North American Group Inc $19,370 5 payments
Amgen Inc. $18,732 4 payments
Celgene Corporation $1,695 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida) $51,530 17 payments
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease $34,771 2 payments
C3718-301 $21,624 2 payments
A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice $18,000 2 payments
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 302 $10,969 3 payments
Phase-2 Study in Subjects with Ulcerative Colitis $10,810 2 payments
A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis Aida $8,401 2 payments
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease $8,200 1 payment
P2 UC $7,921 2 payments
Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis Or Crohn's Disease $3,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.